ADMA Biologics posts Q3 2026 earnings beat and lifts adjusted EBITDA guidance
ADMA Biologics reported third‑quarter 2026 revenue of $141.1 million, up 5.1% year‑over‑year, and GAAP diluted EPS of $0.22, beating estimates. Net income rose to $49.88 million and gross margin expanded to 71% on a gross profit of $99.9 million. The company reiterated its FY2026 revenue target of at least $530 million and raised the minimum adjusted EBITDA outlook to $275 million, citing accelerating demand for ASCENIV. It also repurchased 16.5 million shares for $181.4 million, targeting $200 million of buybacks for the year.
Why it matters
The higher adjusted EBITDA guidance signals stronger profitability than previously expected, which may improve investor sentiment. The ongoing share repurchase program reduces outstanding shares, potentially supporting earnings per share. The unchanged revenue target combined with the EBITDA lift suggests the company expects solid top‑line growth while improving margins.
Key facts
- 1Q3 2026 revenue was $141.1 million, a 5.1% increase from the prior-year quarter. tradingview.com
- 2GAAP diluted EPS for the quarter was $0.22, beating estimates by $0.02. seekingalpha.com
- 3GAAP net income for the quarter was $49.88 million. tradingview.com
- 4Gross profit was $99.9 million and gross margin reached 71%. finance.yahoo.com
- 5FY2026 revenue guidance was reiterated at a minimum of $530 million. seekingalpha.com
- 6Adjusted EBITDA minimum guidance was raised to $275 million for 2026. seekingalpha.com
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.